Security key
55234L105
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA)
CUSIP: 55234L105
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, $0.001 par value
- Total 13F shares
- 300
- Total 13F value
- $26
- Share change
- -25,350,000
- SEC-reported price per share
- $0.09
- Number of holders
- 1
- Value change
- -$3,198,074
- Number of buys
- 1
- Number of sells
- 54
- Shares outstanding
- 1,644,695
Holder snapshot
6 signals
Security identity
1 source field
Report period
Q2 2025
Institutions
1
Top holders
1
LYRA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Previous quarter: Q1 2025
Lyra Therapeutics, Inc. SEC filings
Lyra Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 55234L105
Recent filing periods:
Ownership snapshot
Top reported holders of LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Nantahala Capital Managem...
Disclosed value leader
PERCEPTIVE ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Mar 2025
13D/G
13F
Lead comparable stake: 1.1%
13D/G row: Nantahala Capital Management, LLC
Showing 1-6 of 15 holder rows.
Quick read
Nantahala Capital Management, LLC leads the comparable SEC ownership view at 1.1%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Nantahala Capital Management, LLC
1.1%
PERCEPTIVE ADVISORS LLC
776%
BlackRock, Inc.
184%
VANGUARD GROUP INC
107%
Samsara BioCapital, LLC
85%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC |
13D/G
|
1.1%
|
$84,253
702,106 shares
|
$0 | 30 Sep 2024 |
| PERCEPTIVE ADVISORS LLC |
13F
Company
|
776%
|
$1,607,453
12,757,562 shares
|
— | 31 Mar 2025 |
| BlackRock, Inc. |
13F
Company
|
184%
|
$381,298
3,018,986 shares
|
— | 31 Mar 2025 |
| VANGUARD GROUP INC |
13F
Company
|
107%
|
$222,464
1,765,585 shares
|
— | 31 Mar 2025 |
| Samsara BioCapital, LLC |
13F
Company
|
85%
|
$175,573
1,390,130 shares
|
— | 31 Mar 2025 |
| Ikarian Capital, LLC |
13F
Company
|
64%
|
$133,645
1,058,148 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
300
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
55
Q2 2025 holders
1
Holder diff
-54
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend